gocinirecepti

January 2021: Motor neurone disease treatments that boost energy in nerve cells could be developed thanks to new research. Researchers at the Euan MacDonald Centre for MND Research have recently published the findings of a research study that has provided a new focus for potential drug treatments for MND.   The research team created a […]

Abstract Objective To evaluate progressive white matter (WM) degeneration in amyotrophic lateral sclerosis (ALS).   Methods Sixty-six patients with ALS and 43 healthy controls were enrolled in a prospective, longitudinal, multicenter study in the Canadian ALS Neuroimaging Consortium (CALSNIC). Participants underwent a harmonized neuroimaging protocol across 4 centers that included diffusion tensor imaging (DTI) for

Poštovani pacijenti sa bolešću motoneurona tj. amiotrofičnom lateralnom sklerozom, Zbog velikog broja telefonskih poziva i poruka još jednom želim da Vas zamolim i ohrabrim da je zbog prirode Vaše bolesti neophodno da se vakcinišete protiv Covid 19. Amiotrofična lateralna skleroza nije autoimuna bolest već neurodegenerativna i svakako da se ne očekuje, ni teorijski, neki problem

The Mind Body Connection Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that destroys the neurons that control voluntary muscle movements. The first symptoms of ALS are typically weakness in the limbs and muscle twitches, but the illness eventually disrupts patients’ abilities to move, speak, and even breathe. Treatments exist to extend patient quality

Mindfulness-based programs may help improve anxiety and depression in patients with amyotrophic lateral sclerosis (ALS), according to results of a study published recently in the European Journal of Neurology. The study is titled “Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trial.” The journal also published an editorial written by Jaushin Lou,

ГРАД БЕОГРАД Служба главног урбанисте града Београда упућује Позив особама са посебним потребама за предлоге унапређења њиховог кретања и функционисања у граду Београду Позив свим особама са посебним потребама, као и онима који се баве питањима унапређења њихове свакодневице да пошаљу своје сугестије, предлоге, идеје, као и позиције у Граду које сматрају критичним, како би

The European Medicines Agency has granted orphan drug designation to PrimeC, an investigational combination therapy for amyotrophic lateral sclerosis (ALS).   PrimeC, developed by NeuroSense Therapeutics, also has received orphan drug designation in the United States. The designation, both in the U.S. and Europe, encourages drugmakers to develop therapies for rare and serious diseases by

A pivotal clinical trial evaluating pridopidine for the treatment of amyotrophic lateral sclerosis (ALS) has enrolled its first participant, Prilenia Therapeutics, the medicine’s maker, announced.   The Phase 2/3 study, dubbed HEALEY ALS Platform – Regimen D Pridopidine (NCT04615923), will compare the safety and effectiveness of pridopidine to placebo in an estimated 160 ALS patients,

Dragi članovi, Kako je trenutno aktuelno pitanje vakcinacije za sve građane naše države, pogotovo za smernice o vakcinaciji za osobe obolele od retkih bolesti, ovim putem smo želeli da vas informišemo o nekoliko inostranih online događaja koji se bave pitanjem vakcine i koji vam, nadamo se mogu dati odgovore na neka pitanja koja imate. 1.